TargetBeta
FOLH1
folate hydrolase 1 · also PSM, PSMA, NAALAD1, NAALAdase · M28 metallopeptidases
22 programs in company-led studies act on FOLH1, from 16 companies: 7 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| piflufolastatrule | Lantheus | phase 4 | 51 running | – | NCIt |
| flotufolastat F 18rule | Bracco | phase 4 | 70 running | – | the studies' text |
| abefolastat tesaroxetan CU-64rule | Clarity Pharmaceuticals | phase 3 | 53 running | – | NCIt |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 43 running | – | NCIt |
| Lutetium Lu 177 Ludotadipeprule | FutureChem | phase 3 | 32 running | – | NCIt |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 22 running | – | the company's pipeline |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 22 running | CD28 | a judged reading |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 22 running | – | the company's pipeline |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 22 running | – | NCIt |
| zadavotide guraxetan | AstraZeneca | phase 2 | 44 running | – | a judged reading |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 22 running | CD3E | NCIt |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 22 running | – | the company's pipeline |
| AB-001rule | Frontier Biotechnologies | phase 2 | 31 running | – | the studies' text |
| Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505rule | Regeneron Pharmaceuticals | phase 2 | 11 running | TNFRSF9 | NCIt |
| Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514rule | GlaxoSmithKline | phase 2 | 11 running | CD3E | NCIt |
| HRS-1738 | Jiangsu HengRui Medicine | phase 2 | 11 running | – | the company's pipeline |
| TD001rule | T.O.A.D. Oncology | phase 2 | 11 running | – | the studies' text |
| Autologous Priming Antigen-inducible Anti-PSMA CAR T-cells AB-3028rule | Arsenal Biosciences | phase 2 | 10 running | FAS, TGFB1, TGFBR2 | NCIt |
| Anti-PSMA Antibody-drug Conjugate ARX517 | Johnson & Johnson | phase 1 | 22 running | – | a judged reading |
| Anti-PSMA/CD3 Protease-activated T-cell Engager JANX007rule | Janux Therapeutics | phase 1 | 22 running | – | NCIt |
| Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014rule | Janux Therapeutics | phase 1 | 11 running | CD3E | NCIt |
| Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969 | AbbVie | phase 1 | 11 running | STEAP1 | the company's pipeline |
Conditions their studies are in
- Prostatic Neoplasms, 20 programs
- Prostatic Neoplasms, Castration-Resistant, 4 programs
- Carcinoma, Renal Cell, 3 programs
- Low Back Pain, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 23, 2026gallium 68 PSMA-11 · Novartis · phase 3 · NCT05849298
- Dec 23, 2026zadavotide guraxetan · AstraZeneca · phase 2 · NCT06402331
- Dec 31, 2026abefolastat tesaroxetan CU-64 · Clarity Pharmaceuticals · phase 3 · NCT06970847
- Dec 31, 2026Anti-PSMA Antibody-drug Conjugate ARX517 · Johnson & Johnson · phase 1 · NCT04662580
- Mar 2027SHR-4394 · Jiangsu HengRui Medicine · phase 2 · NCT06783829
- May 2027Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969 · AbbVie · phase 1 · NCT06318273
- Jun 21, 2027Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 · Johnson & Johnson · phase 3 · NCT06095089
- Jul 2027Anti-PSMA/CD3 Protease-activated T-cell Engager JANX007 · Janux Therapeutics · phase 1 · NCT05519449
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.